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The objective of this study was to describe amikacin pharmacokinetics (PK) in critically ill patients receiving equal doses (30
ml/kg of body weight/h) of continuous venovenous hemofiltration (CVVH) and continuous venovenous hemodiafiltration (CV-
VHDF). Patients receiving amikacin and undergoing CVVH or CVVHDF were eligible. Population pharmacokinetic analysis
andMonte Carlo simulation were undertaken using the Pmetrics software package for R. Sixteen patients (9 undergoing CVVH,
11 undergoing CVVHDF) and 20 sampling intervals were analyzed. A two-compartment linear model best described the data.
Patient weight was the only covariate that was associated with drug clearance. The mean standard deviation parameter esti-
mates were 25.2 17.3 liters for the central volume, 0.89 1.17 h1 for the rate constant for the drug distribution from the cen-
tral to the peripheral compartment, 2.38 6.60 h1 for the rate constant for the drug distribution from the peripheral to the
central compartment, 4.45 2.35 liters/h for hemodiafiltration clearance, and 4.69 2.42 liters/h for hemofiltration clearance.
Dosing simulations for amikacin supported the use of high dosing regimens (>25 mg/kg) and extended intervals (36 to 48 h) for
most patients when considering PK/pharmacodynamic (PD) targets of a maximum concentration in plasma (Cmax)/MIC ratio
of>8 and aminimal concentration of<2.5 mg/liter at the end of the dosing interval. The mean clearance of amikacin was 1.8
1.3 liters/h by CVVHDF and 1.3 1 liters/h by CVVH. On the basis of simulations, a strategy of an extended-interval high load-
ing dose of amikacin (25 mg/kg every 48 h) associated with therapeutic drug monitoring (TDM) should be the preferred ap-
proach for aminoglycoside treatment in critically ill patients receiving continuous renal replacement therapy (CRRT). (This
study is a substudy of a trial registered at ClinicalTrials.gov under number NCT01403220.)
Aminoglycosides have been used for many years mostly incombination with other antibiotics to treat infections in
critically ill patients. The optimal dosing regimen should
achieve a pharmacodynamic (PD) target of a maximum con-
centration in plasma (Cmax)/MIC ratio of8 to 10 and an area
under the concentration-time curve (AUC) from time zero to
24 h (AUC0 –24) of70 to 90 and should have the least toxicity
possible, depending on the AUC0 –24 and trough (minimum)
concentrations (Cmins) (1–5). In critically ill patients undergo-
ing renal replacement therapy (RRT), optimization of the an-
tibiotic dosing regimen is a crucial but difficult issue. Critically
ill patients have severely altered pharmacokinetics (PK) (in-
creased volume of distribution or altered drug clearance) due
to hypoalbuminemia, increased capillary permeability, or or-
gan dysfunctions (6, 7). In patients with acute kidney injury
(AKI), the extracorporeal clearance of drugs during RRT could
significantly change antibiotic pharmacokinetics due to the
type of RRT mode, hemofilter, fluid replacement mode (pre- or
postdilution), or RRT settings applied. The physicochemical
properties of the drug also influence the amount of drug
cleared by continuous renal replacement therapy (CRRT). As
amikacin is a small hydrophilic molecule with a very low level
of protein binding, it is likely that CRRT affects amikacin PK.
Instead of intermittent hemodialysis, CRRT techniques are
widely used in critically ill patients, as better hemodynamic
stability and lower metabolic changes associated with possible
better long-term outcomes have been reported (8, 9). These
alterations could dramatically reduce the likelihood of achiev-
ing therapeutic exposures of these drugs.
In previous studies with intensive care unit (ICU) patients un-
dergoing CRRT, amikacin clearance varied from 0.53 to 5.34 li-
ters/h, accounting for 40 to 89% of the total body clearance (10–
15). These studies also reported conflicting results on the
correlation between drug clearance and CRRT settings (11, 14). As
a general rule, it is expected that the efficiency of drug removal
would be higher in continuous venovenous hemodiafiltration
(CVVHDF; diffusive and convective technique) modalities than
in continuous venovenous hemofiltration (CVVH; convective
technique) modalities (16). However, the pharmacokinetics of
amikacin between these two different CRRT modalities using
equal weight-based doses (effluent rate  30 ml/kg of body
weight/h, regardless of the technique used) have never been com-
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pared. Indeed, a better understanding of the influence of different
CRRT modalities on the PK/PD of aminoglycosides in critically ill
patients may lead to optimized dosing strategies that could im-
prove patient care.
The aim of the present study was to describe the pharmaco-
kinetics of amikacin in ICU patients undergoing CVVH or
CVVHDF with equal weight-based doses. Using population
pharmacokinetic modeling and Monte Carlo simulations, we
aimed to determine optimized amikacin dosing regimens for
these patients.
MATERIALS AND METHODS
Setting. This observational pharmacokinetic study was a substudy of a
randomized trial comparing the efficacy of equal doses of CVVH (a 30-
ml/kg/h ultrafiltrate flow rate) and CVVHDF (a 15-ml/kg/h dialysate flow
rate plus a 15-ml/kg/h ultrafiltrate flow rate) in a 16-bed tertiary referral
ICU in Nîmes University Hospital (ClinicalTrials.gov NCT01403220;
completed but as yet unpublished). Ethics approval was obtained from the
local ethics committee of Nîmes, France (Comité de Protection des Per-
sonnes Sud Mediterranée III, 5 February 2012). Written informed consent
was obtained from either the patient or the patient’s nominated substitute
decision maker.
Study population. Patient eligibility for this study was (i) AKI neces-
sitating either CVVH or CVVHDF according to the randomly allocated
mode in the primary study and (ii) a clinical indication for amikacin use.
Patients were randomized to CVVH or CVVHDF (according to the
primary study protocol) when the need for RRT was first identified. If the
patient subsequently had at least an 8-h break from RRT, then the proto-
col of the primary study required that the patient then receive the alter-
native RRT mode. When the patient was on antibiotic therapy across both
RRT modes, the patient was sampled on two different occasions encom-
passing both CVVH and CVVHDF.
Patients were excluded if they had a (i) requirement for RRT for car-
diogenic pulmonary edema, metabolic acidosis (pH 7.15, HCO3 con-
centration, 12 mmol/liter), or hyperkalemia (potassium concentra-
tion, 6.5 mmol/liter) or (ii) a history of allergy to amikacin or a
contraindication to treatment with amikacin.
Renal replacement therapy settings. Both techniques were per-
formed using an Aquarius system (Nikkiso, Japan) and a polysulfone-type
hemofilter with a surface of 1.9 m2 (Aquamax HF19).
The RRT settings were as follows. (i) A 30-ml/kg/h ultrafiltrate rate
was used for CVVH and a 15-ml/kg/h ultrafiltrate rate plus a 15-ml/
kg/h dialysate flow rate were used for CVVHDF. For both techniques, the
replacement mode applied was the postdilution mode. (ii) The net fluid re-
moval rate was set at the physician’s discretion and was between 0 and 200
ml/h. (iii) The targeted blood flow rate was aimed at the provision of a filtra-
tion ratio of 20%. The filtration ratio was calculated as follows: filtration
ratio ultrafiltrate flow rate/blood flow rate. It is the fraction of plasma that
is removed from blood during hemofiltration (17).
Study protocol. A dosing regimen of 15 to 30 mg/kg amikacin was
administered intravenously (i.v.) over 30 min as part of the antimicro-
bial therapy prescribed for the patient. The subsequent doses were
administered at doses and frequencies (typically every 24 or 36 h)
according to the therapeutic drug monitoring results. Prefilter blood
samples to determine plasma amikacin concentrations were taken at
the baseline (predose), at the end of infusion (0.5 h), 30 min after the
end of infusion (1 h), and 1.5, 2, 4, 8, 12, and 24 h after the start of
infusion. Postfilter blood samples were taken up to 2, 4, 8, 12, and 24 h
after the start of infusion.
Sample handling, storage, and measurement. Blood samples were
immediately placed on ice and within 60 min were centrifuged at 3,000
rpm for 10 min and then stored at80°C. Samples were transported by a
commercial courier company to the Burns, Trauma, and Critical Care
Research Centre, The University of Queensland, Brisbane, Queensland,
Australia, for analysis. Amikacin concentrations ranging from 0.5 to 100
mg/liter in plasma were measured by a validated liquid chromatography-
tandem mass spectrometry (LC-MS/MS) method with a hydrophilic in-
teraction liquid chromatography (HILIC) column on a Shimadzu Nexera
system coupled to a Shimadzu 8030 triple-quadrupole mass spectrom-
eter. Clinical samples were assayed alongside calibrators and quality con-
trols and met the batch acceptance criteria of the U.S. Food and Drug
Administration (U.S. FDA).
Sample preparation. Plasma (100 l) was spiked with the internal
standard (vancomycin), and 15% trichloroacetic acid was added to pre-
cipitate the proteins. An aliquot of 0.2 l of the supernatant extract was
injected onto the LC-MS/MS.
Chromatography. The stationary phase was an Agilent Poroshell 120
HILIC column (2.1 by 50 mm, 2.7m, 120 Å). The mobile phase used was
a gradient with mobile phase A, consisting of 0.2% (vol/vol) formic acid,
and mobile phase B, consisting of acetonitrile with 0.2% (vol/vol) formic
acid. The flow rate was 0.3 ml/min.
Validation. The assay method was validated for linearity, lower limit
of quantitation, matrix effects, precision, accuracy, stock solution stabil-
ity, long-term storage stability, and freeze-thaw stability using the U.S.
FDA criteria for bioanalysis. Precision and accuracy were within 8.9%,
2.8%, and 1.5% at the three concentrations tested (1.5, 14, and 60 mg/
liter), respectively. The limit of detection was 0.07 mg/liter.
TABLE 1 Descriptive data for the studied populationa
Demographic data Result
No. of females/no. of males 4/12
Median (IQR) age (yr) 72 (65–75)
Median (IQR) wt (kg) at admission 80 (73–89)
Median (IQR) ht (cm) 167 (162–178)
Median (IQR) body mass index (kg/m2) 27 (24–32)
No. of patients with the following comorbidity:
Hypertension 8
Chronic heart failure 2
COPD 2
Cirrhosis 1
Nondialysis chronic renal disease 2
Median (IQR) severity score
SAPS II at admission 51 (41–59)
SOFA score at admission 10 (8–12)
a Data are for 16 patients. COPD, chronic obstructive pulmonary disease; SAPS II,
simplified acute physiology score II; SOFA, sequential organ failure assessment.
TABLE 2 Clinical data and RRT parameters during RRT sessionsa
RRT Cmax (mg/liter)
Cmin
(mg/liter)
Dosing
interval (h)
12-h urine
output
MAP
(mm Hg)
Heart rate
(no. of beats/min)
Albumin concn
(g/liter)
Creatinine concn
(mol/liter)
CVVHDF (n 11) 52.9 (29.8–68.4) 3.1 (1.6–3.5) 24 (24–38) 110 (98–338) 77 (72–84) 92 (83–102) 27.6 (22–30.7) 243 (191–300)
CVVH (n 9) 60.6 (44.5–86.7) 2.9 (2.5–3) 24.5 (24–34) 700 (30–725) 70 (67–86) 100 (70–106) 27.9 (22.8–29.8) 248 (211–280)
a Data are expressed as the median (IQR). CVVH, continuous venovenous hemofiltration; CVVHDF, continuous venovenous hemodiafiltration; MAP, mean arterial pressure;
RRT, renal replacement therapy; NA, not available.
Roger et al.
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Patient data collection. Additional clinical and demographic data
were collected, including the simplified acute physiology score II (SAPS
II) (18) at ICU admission, the modified sequential organ failure assess-
ment (SOFA) (19) score, comorbidities, and 28-day outcome. During the
RRT treatment, CVVH or CVVHDF settings were also recorded. The type
of infection, the antimicrobial agents administered, microbiological cul-
ture results, and Etest MICs (bioMérieux, Marcy l’Etoile, France) (if avail-
able) were collected.
Population pharmacokinetic modeling. One- and two-compart-
ment models were developed with the nonparametric adaptive grid
(NPAG) algorithm within the freely available Pmetrics software package
for R (Laboratory of Applied Pharmacokinetics, University of Southern
California, Los Angeles, CA) (20, 21). Elimination from the central com-
partment and the intercompartmental distribution (two-compartment
model) into the peripheral compartment were modeled as first-order pro-
cesses.
Population pharmacokinetic covariate screening. Actual body weight,
serum creatinine concentration, serum albumin concentration, age,
SOFA score, vasopressor use, residual renal function, filter age, and the
difference in the patient’s weight between the time of admission and the
sampling day were evaluated as covariates. If inclusion of the covariate re-
sulted in a statistically significant improvement in the log-likelihood values (P
 0.05) and/or improved the goodness-of-fit plots, then it was included.
Model diagnostics. Goodness of fit was assessed by linear regression
with an observed-predicted plot, coefficients of determination, and log-
likelihood values. Predictive performance evaluation was based on the
mean prediction error (bias) and the mean bias-adjusted squared predic-
tion error (imprecision) for the population and individual prediction
models. Using the final covariate model, a visual predictive check (VPC)
was performed using the bootstrapping method by simulating 1,000 sub-
jects to assess the predictive performance of the model.
PTA. Monte Carlo simulations (n  1,000) were employed using
Pmetrics to determine the probability of target attainment (PTA) for
the PK/PD targets, which were a Cmax/MIC ratio of 8 (2, 3, 5) or an
AUC/MIC of 70 (3, 5), for various MICs (0.125 to 32 mg/liter)
during the first 24 h of treatment for patients with total body weights of
60 kg, 80 kg, and 100 kg. Supratherapeutic exposures were described as
a trough concentration (Cmin) of 2.5 mg/liter, in line with French
national guidelines (22).
Fractional target attainment calculation. MIC data for Acinetobacter
baumannii, Klebsiella pneumoniae, Escherichia coli, and Pseudomonas
aeruginosa from the EUCAST database (available at www.eucast.org; ac-
cessed 30 December 2015) were used to determine fractional target attain-
ment. The fractional target attainment identifies the likely success of treat-
ment by comparing the pharmacodynamic exposure (PTA) against an
MIC distribution. A priori, a dosing regimen was considered successful if
the fractional target attainment was85% (34).
Estimation of the clearance of amikacin by CRRT. The clearance of
amikacin by CRRT was assessed as follows: amikacin clearance by CCRT
(CpreCcorpost)/Ccorpost · BFR, whereCpre is the amikacin prehemofilter
concentration,Ccorpost is the corrected amikacin posthemofilter concentra-
tion, and BFR is the blood flow rate. Posthemofilter concentrations were
corrected for postdilution as follows: Ccorpost  Cpost · (BFR  PDR 
FRR)/BFR, where Cpost is the measured amikacin posthemofilter concen-
tration, BFR is the blood flow rate, PDR is the postdilution flow rate, and
FRR is the fluid removal rate.
Statistical analysis. Continuous data are presented as the mean 
standard deviation (SD) or median and interquartile range (IQR). Cate-
gorical data are presented as counts (in percent). Comparisons used the
Mann-Whitney U and chi-square tests as appropriate. Correlations were
assessed by means of a scatter graph and the Pearson correlation coeffi-
cient (r). Differences in amikacin clearance by CVVH and CVVHDF were
analyzed using a Student t test. A P value of0.05 was considered statis-
tically significant, and all analyses were performed using GraphPad Prism
software (version 6.0; San Diego, CA, USA).
RESULTS
Demographic and clinical data. Sixteen patients were recruited
into the study per the study protocol, and data from 20 RRT
sessions were analyzed. Demographic data are presented in Ta-
ble 1. The patients included in the study required vasopressor
support during 17 (85%) RRT sessions. The patients had pul-
monary (n  4), intra-abdominal (n  7), urinary tract (n 
4), and vascular prosthesis (n  1) infections. The samples
studied microbiologically were positive for 7 (44%) patients.
One Serratiamarcescens isolate, one multidrug-resistant (MDR)
K. pneumoniae isolate, three E. coli isolates, one Enterococcus fae-
cium isolate, oneEnterococcus faecalis isolate, oneMorganellamor-
ganii isolate, one MDR Citrobacter braakii isolate, three staphylo-
cocci (including one methicillin-resistant Staphylococcus aureus
isolate and one MDR Staphylococcus capitis isolate), and two
TABLE 2 (Continued)
Urea concn
(mmol/liter)
Blood flow
rate (ml/min)
Dialysate flow
rate (ml/kg/h)
Ultrafiltration
rate (ml/kg/h)
Fraction filtration
ratio (%)
RRT
downtime (h)
Filter age
(h)
Transmembrane
pressure (mm Hg)
Fluid removal
rate (ml/kg/h)
20 (12–25) 200 (180–215) 15.4 (15.1–16.4) 16.3 (14–16.9) 11 (9–12) 0.15 (0–1) 15 (4–21) 39 (20–52) 17 (15–17)
12 (8.2–15.4) 250 (200–250) NA 33.3 (31.2–36.8) 20 (18–21) 0.15 (0–0.75) 15 (14–21) 77 (72–86) 21 (17–21)
FIG 1 Observed mean concentration-time profiles for the amikacin dosing
sampling interval in critically ill patients receiving CVVH (n 9) or CVVHDF
(n 11). Error bars represent standard deviations.
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streptococci were identified. The MICs for the Gram-negative
bacilli ranged from 2 mg/liter to 16 mg/liter. The MICs for the
Gram-positive cocci ranged from 4 to 64 mg/liter. Among the
16 patients included, the 28-day mortality rate was 38%. Four
of the six deaths were related to the infectious episode for
which amikacin was prescribed.
Replacement renal therapy. Four patients underwent both
CVVH and CVVHDF. Of the remaining patients, 5 received CVVH
only and 7 received CVVHDF only. The RRT settings across both
CVVH and CVVHDF treatments are shown in Table 2.
Pharmacokinetic model building. The mean observed con-
centration-time profile of amikacin is shown in Fig. 1. The
blood samples were taken at a median time of 31 h (IQR, 16 to
69 h) after the start of amikacin therapy. A two-compartment
linear model best described the time course of 261 total plasma
concentrations of amikacin. This model included a zero-order
input of drug into the central compartment. The only covariate
that improved the fit of the model was, for amikacin clearance,
weight normalized to 80 kg for CVVH and to 75 kg for
CVVHDF (to the power of 0.75). After the inclusion of weight in the
model, the 2 log-likelihood value was reduced from 801 to 786,
although the log-likelihood values were not statistically significantly
different (P  0.55), and the goodness of fit improved. For these
reasons, weight was retained in the final model.
The final model was described as follows: amikacin CL 
CLhf · [(WT/80)
0.75]  CLhdf · [(WT/75)
0.75], where CL is clear-
ance, WT is total body weight, CLhf is total amikacin clearance on
hemofiltration, and CLhdf is total amikacin clearance on hemodia-
filtration. CLhdf was 0 when hemodiafiltration was applied, and
CLhf was 0 when hemofiltration was applied.
The mean population pharmacokinetic parameter estimates from
the final covariate model were 25.2 17.3 liters for central volume,
0.89  1.17 liters/h for the rate constant for the drug distribution
from the central to the peripheral compartment (kcp), 2.38  6.60
liters/h for the rate constant for the drug distribution from the pe-
ripheral to the central compartment (kpc), 4.45  2.35 liters/h for
population mean total amikacin clearance on hemodiafiltration, and
4.69 2.42 liters/h for population mean total amikacin clearance on
hemofiltration. The mean individual empirical Bayesian clearance
estimates of the patients undergoing CVVH and CVVHDF were es-
timated to be 5.19 0.74 and 4.08 0.50 liters/h (P 0.21), respec-
tively. The diagnostic plots to confirm the goodness of fit of the model
were considered acceptable and are shown in Fig. 2. The final covari-
ate model was then used for dosing simulations.
FIG 2 Diagnostic plots for the final covariate model. Observed versus population predicted concentrations (top right) and individual predicted concentrations
(top left) in plasma. (Bottom) Visual predictive check. CI, confidence interval. Inter, intercept.
Roger et al.
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Dosing simulations. The Monte Carlo simulations and PTAs
of a Cmax/MIC ratio of 8 and an AUC/MIC of 70 for various
amikacin doses for patients that weighed 60 kg, 80 kg, or 100 kg are
described in Table 3. The Monte Carlo simulations and PTAs of a
Cmax/MIC ratio of 8 and a Cmin of 2.5 mg/liter for various
amikacin dosing regimens for a patient that weighed 80 kg and for
an isolate for which the MIC was 4 mg/liter are shown in Fig. 3
(CVVH) and Fig. 4 (CVVHDF). An MIC of 4 mg/liter was
chosen to indicate that suboptimal achievement of therapeutic
targets occurs at this MIC.
Fractional target attainment. The fractional target attain-
ments for the simulated PTAs for a range of amikacin doses, dose
intervals, and patient body weights against susceptible MIC distri-
butions (MICs 8.0 mg/liter) for A. baumannii, K. pneumoniae,
E. coli, and P. aeruginosa are shown in Table 4.
Amikacin clearance across the hemofilter during CRRT. The
mean clearance of amikacin by CRRT was 1.8  1.3 liters/h by
CVVHDF and 1.3 1.0 liters/h by CVVH.
DISCUSSION
In the present study, the extended-interval high amikacin dose of
25 mg/kg every 48 h is optimal in critically ill patients undergoing
CVVH or CVVHDF to achieve the PK/PD targets and to limit
toxicity when infections with difficult-to-treat pathogens are sus-
pected. Indeed, this dose and dosing interval led to the optimal
amikacin exposure, as this dosing regimen provides the largest
TABLE 3 Monte Carlo simulations and PTA in plasma for various i.v. amikacin doses for patients with body weights of 60 kg, 80 kg, and 100 kg
undergoing CVVH or CVVHDF for various MICsa
RRT, body wt,
and dosage
Achievement of the indicated PK/PD target for MIC of:
1 mg/liter 2 mg/liter 4 mg/liter 8 mg/liter
Cmax/MIC
ratio 8 AUC/MIC 70
Cmax/MIC
ratio 8 AUC/MIC 70
Cmax/MIC
ratio 8 AUC/MIC 70
Cmax/MIC
ratio 8 AUC/MIC 70
CVVH
60 kg
15q24        
20q24        
25q24        
30q24        
35q24        
80 kg
15q24        
20q24        
25q24        
30q24        
35q24        
100 kg
15q24        
20q24        
25q24        
30q24        
35q24        
CVVHDF
60 kg
15q24        
20q24        
25q24        
30q24        
35q24        
80 kg
15q24        
20q24        
25q24        
30q24        
35q24        
100 kg
15q24        
20q24        
25q24        
30q24        
35q24        
a The target was a Cmax/MIC ratio of8 and AUC/MIC of70. CVVH, continuous venovenous hemofiltration; CVVHDF, continuous venovenous hemodiafiltration;,
achievement of PK/PD target;, nonachievement of PK/PD target; 15q24, 20q24, 25q24, 30q24, and 35q24, doses of 15, 20, 25, 30, and 35 mg/kg administered every 24 h,
respectively.
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difference between the efficacy and the toxicity probability (23).
Several studies have reported that the pharmacokinetics of amin-
oglycosides are altered in critically ill patients, leading to a Cmax
lower than the targeted Cmax in 30 to 40% of critically ill patients
using standard dosing regimens (24–27). The increased volume of
distribution observed in critically ill patients and the concentra-
tion-dependent killing activity of aminoglycosides support the use
of regimens with higher doses of amikacin to achieve adequate
Cmaxs. The use of dosing regimens of 25 mg/kg in critically ill
patients has been suggested by several authors and recommended
by some national guidelines (13, 24, 27, 28). However, some con-
cerns remain about aminoglycoside-related nephrotoxicity using
high aminoglycoside dosing regimens, especially in patients with
AKI requiring RRT. Our results showed that the PK/PD targets
(Cmax/MIC ratio 8, AUC/MIC 70) were achieved with a dos-
ing regimen of 25 mg/kg or higher in critically ill patients under-
going CVVH or CVVHDF. These results are consistent with those
reported by Taccone et al. (11). They reported that a 25-mg/kg
loading dose of amikacin in patients undergoing CVVHDF at a
dose of 30 ml/kg/h and a blood flow rate setting at 150 to 200
ml/min achieved the targeted Cmax of 64 mg/liter in 9 (69%) pa-
FIG 3 PTA of efficacy (Cmax/MIC ratio 8) and toxicity (Cmin 2.5 mg/liter
at the end of the dosing interval) for a patient undergoing CVVH with a body
weight of 80 kg with dosing every 24 h (q24) (a), 36 h (q36) (b), and 48 h (q48)
(c) and targeting pathogens with an MIC of 4 mg/liter.
FIG 4 PTA of efficacy (Cmax/MIC ratio 8) and toxicity (Cmin 2.5 mg/liter
at the end of the dosing interval) for a patient undergoing CVVHDF with a
body weight of 80 kg with dosing every 24 h (a), 36 h (b), and 48 h (c) and
targeting pathogens with an MIC of 4 mg/liter. Units for dosing are milligrams
per kilogram.
Roger et al.
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tients. The amikacin clearance reported in that study widely varied
between 0.006 and 0.198 liter/kg/h, but the mean clearance of
amikacin was lower than that reported in the present study (11).
The authors did not find any correlation between RRT settings
and amikacin clearance. However, some RRT parameters, such as
pre- or postdilution mode or downtime, were not recorded. RRT
filter downtime is also a factor that may influence RRT-related
drug clearance but is rarely reported. In the present study, the
filter downtime was very low during the dosing interval and likely
did not affect amikacin clearance, and only the postdilution mode
was used.
As CVVHDF combines convection and diffusion processes to
clear molecules from blood, there is a general assumption that
clearance by CVVHDF is higher than clearance by CVVH (16). In
the present study, using the recommended 30-ml/kg/h effluent
rate for both modes (a 30-ml/kg/h ultrafiltrate flow rate for CVVH
and a 15-ml/kg/h dialysate flow rate associated with a 15-ml/kg/h
ultrafiltrate flow rate for CVVHDF) (29), similar blood flow rates,
and similar membranes during the RRT sessions, we did not show
any significant differences in amikacin clearance. It could be hy-
pothesized that when the recommended high doses of the effluent
rate for continuous RRT are applied, the difference between con-
vection and/or diffusion might not be significant for antibiotic
pharmacokinetics (30).
Most importantly, none of the simulated dosing regimens
achieved the PK/PD targets for the EUCAST MIC breakpoint of 8
mg/liter. These findings might encourage physicians to increase
amikacin doses, but the increasing risk of renal toxicity should be
considered. As the clearance decreases in the context of AKI, the
drug half-life increases, in which case an extended dosing interval
would be required to enable redosing at the recommended trough
concentrations. In the present study, extended intervals (i.e., every
36 h up to every 48 h) achieved the lowest probability of toxicity
without an apparent decrease in efficacy. Extending the dosing
interval may allow a drug-free period and may reduce the risk of
aminoglycoside accumulation in the renal cortex. In a previous
study, we highlighted that the use of a regimen with a higher dose
(30 mg/kg) in association with therapeutic drug monitoring led to
extended dosing intervals in half of the critically ill patients stud-
ied (28). Taccone et al. reported that the median time to achieve a
trough concentration below 5 mg/liter was 36 h (IQR, 14 to 76 h)
in patients undergoing CVVHDF (11). The extended dosing in-
TABLE 4 Fractional target attainment for the various amikacin doses every 24 h for patients with body weights of 60 kg, 80 kg, or 100 kg receiving
CVVH or CVVHDF for susceptible MIC distributions for A. baumannii, K. pneumoniae, E. coli, and P. aeruginosaa
Body wt (kg) i.v. dose (mg/kg)b RRT
Fractional target attainmentc (%)
A. baumannii K. pneumoniae E. coli P. aeruginosa
60 900 (15) CVVHDF 65 91 73 53
CVVH 53 83 60 40
1,200 (20) CVVHDF 74 94 82 64
CVVH 74 94 82 64
1,500 (25) CVVHDF 82 96 88 74
CVVH 82 96 88 75
1,800 (30) CVVHDF 88 97 93 83
CVVH 88 95 89 83
2,100 (35) CVVHDF 92 98 96 88
CVVH 92 98 96 88
80 1,200 (15) CVVHDF 74 94 82 64
CVVH 53 83 59 40
1,600 (20) CVVHDF 84 96 90 77
CVVH 85 96 90 78
2,000 (25) CVVHDF 91 98 95 86
CVVH 91 98 95 86
2,400 (30) CVVHDF 94 98 97 91
CVVH 94 98 97 91
2,800 (35) CVVHDF 96 99 98 94
CVVH 96 99 98 94
100 1,500 (15) CVVHDF 82 96 88 74
CVVH 53 82 59 40
2,000 (20) CVVHDF 84 96 90 77
CVVH 91 98 95 86
2,500 (25) CVVHDF 91 98 95 86
CVVH 94 98 97 91
3,000 (30) CVVHDF 94 98 97 91
CVVH 97 99 98 95
3,500 (35) CVVHDF 96 99 98 94
CVVH 98 100 99 98
a CVVH, continuous venovenous hemofiltration; CVVHDF, continuous venovenous hemodiafiltration.
b Weight-based dosing regimens (in milligrams per kilogram) are given in parentheses.
c Gray shading, achievement of the a priori PTA of a Cmax/MIC ratio of8 against at least 85% of isolates.
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tervals suggested by the results of the present study are consistent
with recommendations for aminoglycoside dosing regimens in criti-
cally ill patients receiving continuous RRT (30–32). However, as
highlighted by the results of the present study, regimens with
doses higher than those recommended (e.g., a loading dose of 10
mg/kg and maintenance doses of 7.5 mg/kg every 24 to 48 h)
should be used to ensure efficacy and to limit toxicity at the same
time. Some authors have even suggested that a dosing regimen of
50 mg/kg of amikacin followed by continuous RRT be used to
limit toxicity in a patient with a multidrug-resistant P. aeruginosa
infection (33).
The present study has limitations to consider. First, we could
not assess mechanistically if the concentrations observed were
caused by RRT or non-RRT clearance because the clearance of
amikacin into the RRT effluent was not available in this study,
although this limitation does not alter our dosing recommenda-
tions. Moreover, no correlation between residual renal function
and amikacin clearance was found in this model. Second, we used
a targeted trough concentration of 2.5 mg/liter to define amin-
oglycoside-related renal toxicity, even though its relevance could
be questioned. However, French guidelines recommend redosing
only when aminoglycoside trough concentrations are below 2.5
mg/liter. Third, further prospective studies need to confirm that
extended dosing intervals do not reduce the antimicrobial effects
of aminoglycosides.
Conclusion. In the present study, we observed a high degree
of variability in the pharmacokinetics of amikacin in critically
ill patients. Suboptimal achievement of therapeutic targets for
the EUCAST breakpoint of 8 mg/liter occurs when standard
dosing is used. We recommend a loading dose of 25 mg/kg
every 48 h adjusted according to the findings of therapeutic
drug monitoring as the preferred approach for aminoglycoside
treatment in critically ill patients receiving continuous renal
replacement therapy.
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